Question 9639 — research and innovation

Summary

The Government is very keen to encourage research into therapeutic innovations by allowing patients to have access to them as early as possible, whether they are medicines, medical devices, professional acts and/or organizations. Several systems have been put in place in France for this purpose, including temporary authorizations for use (ATU) for medicines. On the occasion of the Council Strategic Health Industries Strategy (CSIS) on July 9 and 10, the Government presented several measures aimed at improving the competitiveness and attractiveness of France in the field of health, particularly in the research and development of biomedicines, as well as innovative therapies. With regard to rare diseases, the Government has given this theme a marked priority and, in this approach, it has desired the existence of a 3rd National Rare Disease Plan, as announced on July 4, 2018. France widely supports research, particularly for rare diseases, at the national level, through funding for different programs, on the basis of calls for projects, which regularly include research on this theme but also through the France Genomic Medicine 2025 plan with the funding of 2 genomic platforms aimed diagnostic and therapeutic, as well as through the certification of reference centers and research sectors on the subject of rare diseases. The national rare diseases plan 3 also endorses the launch of a French research program on diagnostic impasses as well as France's participation and financing in the European Joint Program Rare Diseases, thus strengthening the European and international dimension of the French research on rare diseases. France is therefore strongly committed to supporting therapeutic innovation, particularly in the field of rare diseases.

Machine translation from French. The official text remains authoritative.

Timeline

No timeline events have been ingested for this record yet.

Votes

No vote records are attached yet.

Versions

No version snapshots stored. Document URLs remain at the source.

Documents

No documents linked.

Sponsors

No sponsors or actors listed by the source.

Related records

No cross-record relationships stored yet.